Marc Casper, Thermo Fisher Scientific CEO (Photo by Suzanne Kreiter/The Boston Globe via Getty Images)

Af­ter a busy year of build­outs, Ther­mo Fish­er sets plans for growth in 2023

Last year, Ther­mo Fish­er ex­pand­ed wide­ly across the US and abroad. This year, how­ev­er, it’s ex­pect­ing a big dip in vac­cine and ther­a­peu­tics rev­enue.

The com­pa­ny brought in $44.92 bil­lion in rev­enue last year, a growth of 15%, with rev­enues in the fourth quar­ter to­tal­ing $11.45 bil­lion, a 7% growth from 2021. On the in­vest­ment call, Ther­mo Fish­er CEO Marc Casper said that its phar­ma and biotech sec­tor had “im­pres­sive per­for­mance” with growth in the low teens for the quar­ter and mid-teens for the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA